1. Introduction {#sec1-ijms-21-00086}
===============

Retinitis pigmentosa (RP) defines a clinically heterogeneous group of inherited retinal dystrophies presenting with bilateral, progressive degeneration of photoreceptors (primarily rods) leading to night blindness, reduced-to-undetectable electroretinogram (ERG) amplitudes, peripheral field restriction, variable loss of central vision, and typical pigmentary degeneration of the retina \[[@B1-ijms-21-00086]\]. The disorder has a prevalence of approximately 1 in 3000--4000 individuals with a total of more than one million affected people worldwide \[[@B1-ijms-21-00086]\]. The clinical manifestation of RP is predominantly confined to the eye and the retina. However, approximately 20--30% of patients have extra-ocular involvement. Usher syndrome presenting with RP associated with hearing impairment is the most frequent condition among these syndromic cases \[[@B1-ijms-21-00086]\].

Over 130 genes have been found to be responsible for RP (<http://www.sph.uth.tmc.edu/RetNet>; accessed on September 2019), with approximately 90 genes responsible for isolated, non-syndromic RP and about 40 genes for syndromic forms. The causative genes encode for proteins involved in a variety of fundamental processes that are responsible for the visual cycle, phototransduction, photoreceptor outer segment structure, and house-keeping functions such as transcription, RNA processing and ciliary function among others \[[@B2-ijms-21-00086]\].

Several RP subtypes have been clinically defined. Among them, pericentral RP is an atypical form with better preservation of the far periphery as a major distinctive feature. Specifically, subjects with pericentral RP display bone-spicule pigmentation or atrophy in the near mid-periphery while the far periphery, within and beyond the vascular arcades, is overall preserved leading to annular scotoma from 5--30 degrees ([Figure 1](#ijms-21-00086-f001){ref-type="fig"}). In these patients, full-field ERG responses are subnormal, yet still detectable \[[@B3-ijms-21-00086]\].

Until now, the clinical features and genetic causes of pericentral RP have been reported only in non-European populations, by Comander et al. in 43 patients \[[@B4-ijms-21-00086]\], Matsui et al. in 28 patients \[[@B5-ijms-21-00086]\] and Sandberg et al. in 45 patients \[[@B3-ijms-21-00086]\]. These reports described the clinical phenotypes in the different pericentral RP populations by monitoring the progress of the disease through the main morphological and functional parameters and compared the causative genes identified. Despite valuable insights on the genetic basis of this subtype of RP, precise genotype-phenotype correlations are yet to be firmly established.

In this study, we performed a detailed analysis of a large cohort of Italian patients with pericentral RP at the clinical and genetic levels. Our aim was to describe in depth the clinical features, to define the genetic causes by next-generation sequencing (NGS)-based procedures and to investigate possible genotype-phenotype correlations. To our knowledge, this is the first study of a European cohort of pericentral RP patients.

2. Results {#sec2-ijms-21-00086}
==========

2.1. Ophthalmological Characterization of Pericentral Retinitis Pigmentosa (RP) Patients {#sec2dot1-ijms-21-00086}
----------------------------------------------------------------------------------------

A total of 54 Italian patients from 48 independent families with pericentral RP at the time of presentation were recruited for the study. The majority of patients (*n* = 39) were sporadic cases with the exception of 15 families showing an autosomal recessive (*n* = 11) or an autosomal dominant (*n* = 4) pattern of inheritance ([Table S1](#app1-ijms-21-00086){ref-type="app"}).

Subject mean age was 47.7 ± 18.9 years (range: 11--92 years) with a mean age of onset of 26.8 ± 17.8 years (range: 8 months--64 years) ([Table 1](#ijms-21-00086-t001){ref-type="table"}, [Table S1](#app1-ijms-21-00086){ref-type="app"}). Patients reported the following symptoms: night blindness (*n* = 26; 48.1%), reduction of visual acuity (*n* = 10; 18.5%), narrowing of visual field (*n* = 9; 16.7%) and photophobia (*n* = 6; 11.1%) ([Table 1](#ijms-21-00086-t001){ref-type="table"}, [Table S1](#app1-ijms-21-00086){ref-type="app"}). Only one patient (1.5%) presented nystagmus at the age of 8 months ([Table S1](#app1-ijms-21-00086){ref-type="app"}). In 12 patients (22.2%) the diagnosis of RP was incidentally made ([Table S1](#app1-ijms-21-00086){ref-type="app"}).

In terms of clinical manifestations, the pericentral RP cohort included patients diagnosed with isolated RP (*n* = 42) as well as patients presenting syndromic forms (*n* = 12) ([Table S1](#app1-ijms-21-00086){ref-type="app"}). Specifically, 11 patients presented bilateral sensorineural hearing loss and were diagnosed with Usher syndrome type 2. Retrospectively, following the genetic analysis, one patient showing also amelogenesis imperfecta and nail abnormalities in addition to RP and hearing loss was diagnosed with Heimler syndrome (as explained below).

Mean best corrected visual acuity (BCVA) was 0.7 ± 0.3 decimals ranging from light perception to 20/20 in both eyes, with the vast majority of patients (*n* = 46; 85.2%) achieving a BCVA of 20/40 or better in at least one eye ([Table S1](#app1-ijms-21-00086){ref-type="app"}). Refractive errors were on average −0.24 ± 2.37 diopters (D) and −0.15 ± 2.48 D in RE and LE, respectively, ranging from −4.00 D to 8.75 D ([Table S1](#app1-ijms-21-00086){ref-type="app"}). The lens was clear in both eyes in 32 patients (59.3%), 12 patients (22.2%) showed initial lens opacity in both eyes, 6 patients (11.1%) showed subcapsular posterior opacity in both eyes, 3 patients (5.6%) were pseudophakic in both eyes, and 1 patient (1.9%) displayed subcapsular lens opacity in one eye and pseudophakia in the other eye ([Table S1](#app1-ijms-21-00086){ref-type="app"}). The fundus of all patients was characterized by pigment accumulations within and beyond the vascular arcades while the far periphery had a normal appearance ([Figure 1](#ijms-21-00086-f001){ref-type="fig"}b).

The pericentral RP patients displayed different patterns of visual field loss. Specifically, we identified pericentral field loss in 43 eyes (43.9%), constricted with ring scotoma in 29 eyes (29.6%), constricted with peripheral scotoma in 9 eyes (9.2%), concentric constricted in 15 eyes (15.3%) and central scotoma in 2 eyes (2.0%). The mean Goldmann visual field examination (GVF) area using III4e target size was 3984.5 ± 2424.3^°2^ and 4041.6 ± 2497.3^°2^ in the right and left eyes, respectively. The mean GVF area using V4e target size was 7716.7 ± 3948^°2^ and 8332.3 ± 4486.7^°2^ in the right and left eyes, respectively ([Table 1](#ijms-21-00086-t001){ref-type="table"}).

All patients underwent full-field ERG. Dark-adapted 0.01 responses (formerly called 'rod response') were below noise level in 15 patients (27.8%) and were reduced in 39 patients (72.2%) (mean b-wave amplitude: 28.7 ± 33.9 µV in RE; 28.2 ± 28.9 µV in LE; normal range: 95--305 µV) ([Table S1](#app1-ijms-21-00086){ref-type="app"}). Dark-adapted 3.0 responses (formerly called 'mixed response') were subnormal (mean b-wave amplitude: 76.8 ± 70.9 µV and 80.9 ± 76.8 µV; normal range: 290--654 µV) in all analyzed patients ([Table S1](#app1-ijms-21-00086){ref-type="app"}). Light-adapted 3.0 and 30 Hz were subnormal in all patients but one, who showed normal responses. Mean b-wave amplitude in light-adapted 3.0 were 36.3 ± 27.4 µV and 36.7 ± 26.6 µV (normal range: 103--250 µV) in the right and left eyes, respectively ([Table S1](#app1-ijms-21-00086){ref-type="app"}). Mean P1-N1 amplitude in light-adapted 30 Hz responses were 23.9 ± 19.9 µV and 23.9 ± 19.4 µV (normal range: 57--223 µV) in the right and left eyes.

Optical coherence tomography (OCT) evaluation was performed in 50 pericentral RP patients ([Table S1](#app1-ijms-21-00086){ref-type="app"}). Over half of the patients (55 eyes; 55.0%) showed vitreo-macular abnormalities (mean age: 46.4 ± 17.5 years). Forty-five eyes (45%) did not display any of the aforementioned macular alterations and had mean central retinal thickness (CRT) values at the range of 242.9 ± 47.3 µm, with reduced values in only 15 out of the 45 eyes (33.3%) (normal range: 270.2 ± 22.5 µm) ([Table S1](#app1-ijms-21-00086){ref-type="app"}). Cystoid macular edemas (CME) were observed in 14 eyes (14.0%). Specifically, six patients showed bilateral CME and two patients showed CME only in one eye ([Table S1](#app1-ijms-21-00086){ref-type="app"}). Epiretinal membranes (ERM) were observed in 15 eyes (15.0%): four patients had ERM bilaterally while nine patients showed ERM only in one eye ([Table S1](#app1-ijms-21-00086){ref-type="app"}). One patient showed a bilateral lamellar macular hole ([Table S1](#app1-ijms-21-00086){ref-type="app"}). The ellipsoid zone (EZ) band was measured in 46 patients (92.0%) with mean values of 2007 ± 1129 µm and 1964 ± 1116 µm in the right and left eyes, respectively ([Table S1](#app1-ijms-21-00086){ref-type="app"}). For 4 patients (8.0%) the EZ band could not be assessed, because was absent, in both eyes.

For 24 patients (44.4%) fundus autofluorescence (FAF) imaging was performed ([Table S1](#app1-ijms-21-00086){ref-type="app"}). Large areas of hypo-fluorescence were evident along the vascular course in all FAF analyses. Two patients (8.3%) had a normal macular autofluorescence in both eyes, whereas abnormal foveal hypo-autofluorescence was detected bilaterally in 4 patients (16.7%). The typical ring of perimacular hyper-autofluorescence was observed in 15 patients (62.5%). The rings were located at the posterior pole, inside vascular arcades, and its average width was 243 ± 236 µm in the right eyes and 243 ± 235 µm in the left eyes ([Table S1](#app1-ijms-21-00086){ref-type="app"}). We also found a strong correlation between the width of the EZ band and the horizontal diameter of the external boundary of the hyper-autofluorescent ring (ρ \> 0.9; *p*-value \< 0.001). Finally, a hyper-autofluorescent foveal patch was seen in 3 patients (12.5%).

Nineteen patients (35.2%) performed microperimetry (MP1) ([Table S1](#app1-ijms-21-00086){ref-type="app"}). Mean retinal sensitivity was 5.5 ± 5.8 dB and 4.7 ± 5.1 dB in the left and right eyes, respectively. The fixation was stable in 22 out of the 38 eyes (57.9%), relatively stable in 11 eyes (28.9%) and unstable in 5 eyes (13.2%) ([Table S1](#app1-ijms-21-00086){ref-type="app"}). Nine patients showed a stable fixation in both eyes, while fixation was relatively stable in 4 patients and unstable in 2 patients.

2.2. Genetic Analysis {#sec2dot2-ijms-21-00086}
---------------------

A total of 39 patients (from 35 unrelated families), clinically classified as pericentral RP, gave their informed consent to genetic testing. Genomic DNA was analyzed by targeted NGS using either panel-based sequencing of known retinopathy genes or a more comprehensive clinical exome sequencing aiming at sequencing more than 2700 genes responsible for Mendelian disorders.

Causative mutations were found in 22 out of 35 analyzed families (63% diagnostic rate). Pathogenic or likely pathogenic variants were identified in the following genes: *USH2A* in 9 families (representing 41% of solved cases and 25.7% of total cases); *CEP290* in 2 families (9%; 5.7%); *RP1* in 2 families (9%); *PRPF31* in 2 families (9%; 5.7%); *PDE6B* in 2 families (9%; 5.7%); *BBS2* in 1 family (4.5%; 2.8%); *NR2E3* in 1 family (4.5%; 2.8%); *PEX1* in 1 family (4.5%; 2.8%); *PRPH2* in 1 family (4.5%; 2.8%); *RHO* in 1 family (4.5%; 2.8%) ([Table 2](#ijms-21-00086-t002){ref-type="table"}; [Figure 2](#ijms-21-00086-f002){ref-type="fig"}a). Pathogenic variants were validated by Sanger sequencing. Segregation analysis was performed whenever possible, confirming the expected zygosity state and the presence of the pathogenic variants in *trans*.

Thirteen of the 34 putatively pathogenic variants identified in this study ([Table 2](#ijms-21-00086-t002){ref-type="table"}) have not been previously described, as assessed by cross-checking the entries in the Human Gene Mutation Database (HGMD) or the Leiden Open Variation Database (LOVD) ([Table 3](#ijms-21-00086-t003){ref-type="table"}). The novel variants included one nonsense variant in *RP1* (c.2219C \> G), two frameshift variants in *RP1* (c.2978delC) and *PRPF31* (c.690delG), two splicing variants in *CEP290* (c.5709 + 2T \> G) and in *USH2A* (c.5776 + 1G \> C), a non-frameshift insertion in *PEX1* (c.2145_2146insTCTCAG) and seven missense variants (in *CEP290*, *PRPF31*, *RHO*, and *USH2A*) ([Table 3](#ijms-21-00086-t003){ref-type="table"}). The pathogenicity of the missense variants was corroborated by in silico predictions of their impact on protein function ([Table 3](#ijms-21-00086-t003){ref-type="table"}) and by segregation analysis, whenever possible.

The aforementioned genetic analysis allowed us to detect a high frequency of pathogenic variants in genes that are usually associated with syndromic RP ([Figure 2](#ijms-21-00086-f002){ref-type="fig"}b). Collectively, 59% of the patients with pericentral RP harbored mutations in *BBS2*, *CEP290*, and *USH2A* which, besides non-syndromic forms, are responsible for Bardet-Biedl syndrome ([www.omim.org/entry/606151](www.omim.org/entry/606151)), Joubert, Meckel and Senior-Loken syndromes ([www.omim.org/entry/610142](www.omim.org/entry/610142)), and Usher syndrome type 2 ([www.omim.org/entry/608400](www.omim.org/entry/608400)), respectively. Interestingly, one of the analyzed patients (P27) was found to harbor two putatively pathogenic variants (c.2145_2146insTCTCAG and c.274G \> C; in *trans)* in the *PEX1* gene, which is responsible for a perixosome biogenesis disorder (i.e., Heimler syndrome) ([www.omim.org/entry/602136](www.omim.org/entry/602136)). Indeed, a more careful clinical re-evaluation of P27 revealed the presence of signs compatible with Heimler syndrome, such as dental anomalies and sensorineural hearing loss (Barillari et al., manuscript in preparation).

*USH2A*, which is the most common genetic cause of Usher syndrome, was the most frequently mutated gene in our cohort, accounting for over one third of the cases analyzed (9 out of the 25 solved familial cases). Eight patients (7 families) harboring mutations in *USH2A* displayed pericentral RP in the context of an Usher syndrome type II, whereas the other two patients with causative variants in *USH2A* showed a normal audio-vestibular response.

Intriguingly, almost two thirds of the solved cases of pericentral RP (i.e. 14 out of 22) harbored putatively pathogenic mutations in genes involved in ciliary development and function, such as *BBS2* (one case), *CEP290* (two cases), *RP1* (two cases) and *USH2A* (nine cases) ([Figure 2](#ijms-21-00086-f002){ref-type="fig"}c).

2.3. Intrafamilial Variability of Pericentral RP {#sec2dot3-ijms-21-00086}
------------------------------------------------

The ophthalmological analysis of our pericentral RP cohort revealed marked intrafamilial phenotypic variability in at least three cases.

In the case of family n. 3, both offspring of unaffected parents were diagnosed with RP ([Figure 3](#ijms-21-00086-f003){ref-type="fig"}a). One of the siblings (II:2) was diagnosed with pericentral RP and was included in our cohort (P4; [Table 1](#ijms-21-00086-t001){ref-type="table"}). This patient, at the age of 49, displayed as first symptoms a reduction of visual field, preserved BCVA (20/23 in both eyes), the typical pericentral retinal phenotype at the fundus examinations (II:2 in [Figure 3](#ijms-21-00086-f003){ref-type="fig"}c), constricted visual field with ring scotoma, and subnormal dark-adapted 0.01 and light-adapted ERG responses ([Table S1](#app1-ijms-21-00086){ref-type="app"}). His affected sister, during a routine ophthalmological visit at the age of 57, showed a sector form of RP (i.e., bone-spicule localized in the nasal sector)(II:1 in [Figure 3](#ijms-21-00086-f003){ref-type="fig"}c) with preserved visual acuity (20/20 in both eyes), slightly constricted visual field, dark-adapted 0.01 ERG response below noise level, and subnormal light-adapted ERG responses. Both affected siblings were found to carry compound heterozygous pathogenic variants (c.1107 + 3A \> G and c.1798G \> A) in the *PDE6B* gene ([Table 2](#ijms-21-00086-t002){ref-type="table"}, [Figure 3](#ijms-21-00086-f003){ref-type="fig"}b).

We observed phenotypic variability also in family n. 25 between patient P29 ([Table 1](#ijms-21-00086-t001){ref-type="table"}) and her affected brother. The proband (P29) showed typical pericentral RP findings with incidental diagnosis at the age of 9, BCVA of 20/200 in right eye and 20/30 in left eye, the typical pericentral retinal phenotype at the fundus examination, pericentral visual field loss, subnormal dark-adapted 0.01 and light-adapted ERG responses ([Table S1](#app1-ijms-21-00086){ref-type="app"}). Instead, her brother was diagnosed at 20 years with typical RP, characterized by a severely restricted visual field (10° using target size III4e) and ERG responses below noise level. Molecular analysis revealed that both affected siblings were compound heterozygous for two likely pathogenic variants (c.3045C \> G and c.6992G \> A) in the *USH2A* gene ([Table 2](#ijms-21-00086-t002){ref-type="table"}). Segregation analysis in the family suggested that the variants were in *trans*. Hearing tests did not reveal any audio-vestibular alterations in either patient.

Finally, in family n. 43, the daughter of patient P49 ([Table 2](#ijms-21-00086-t002){ref-type="table"}), during a routine ophthalmological visit at the age of 25 years, showed a sector form of RP (i.e., bone-spicule localized in the temporal sector), with ERG responses at the lower limit of the normal range and a slightly reduced visual field. On the other hand, P49 displayed a disease onset at the age of 42 with night blindness and reduction of visual field, preserved BCVA (20/20 in both eyes), the typical retinal phenotype at the fundus examination, pericentral visual field loss, subnormal dark-adapted 0.01 and light-adapted ERG responses ([Table S1](#app1-ijms-21-00086){ref-type="app"}). Genetic analysis was performed in both patients but no convincing pathogenic variants were identified.

3. Discussion {#sec3-ijms-21-00086}
=============

In the present study, we provide a comprehensive clinical and genetic evaluation of subjects with pericentral RP. To our knowledge, this study includes the largest cohort of subjects (54 cases from 48 unrelated families) of European origin with pericentral RP.

Consistent with previous reports \[[@B21-ijms-21-00086]\], we found that pericentral RP is a rather uncommon RP subtype and has extensive genetic heterogeneity. Genetic defects underlying pericentral RP are overall overlapping those causing mild forms of typical RP, as previously suggested \[[@B4-ijms-21-00086]\]. While previous studies \[[@B3-ijms-21-00086],[@B4-ijms-21-00086],[@B5-ijms-21-00086]\] found pericentral RP cases almost exclusively in the context of non-syndromic forms, we observed a high prevalence of pericentral RP within the syndromic RP group, mainly in Usher syndrome. In agreement, variants in *USH2A* were detected in over 40% of the solved cases in our cohort. A high frequency of *USH2A* mutations among cases with pericentral RP has not been previously reported \[[@B4-ijms-21-00086],[@B5-ijms-21-00086],[@B22-ijms-21-00086],[@B23-ijms-21-00086]\]. Different studies identified *RHO* \[[@B4-ijms-21-00086],[@B24-ijms-21-00086]\] or *ABCA4* \[[@B5-ijms-21-00086]\] defects as the most common cause. The inclusion criteria for each study cohort may partly account for this difference. Specifically, Matsui et al. included only subjects with non-syndromic retinal degenerations, while Grondahl et al. analyzed only four genes (*RHO*, *RP1*, *PRPH2* and *IMPDH1*) that did not comprise *USH2A*. Our cohort can be directly compared to the study of Comander et al. which recruited 45 cases with pericentral RP without excluding syndromic forms \[[@B4-ijms-21-00086]\]. In that report, *USH2A* gene defects were identified in 14.3% of solved cases, whereas mutations in the *HGSNAT* gene (typically responsible for Mucopolysaccharidosis type IIIC \[[@B25-ijms-21-00086]\]) were a relatively common cause of pericentral RP \[[@B4-ijms-21-00086]\]. However, the cohorts' size (i.e., 54 and 45 cases) does not allow to discuss further the discrepancies in mutation frequency. An expansion of the pericentral RP cohorts analyzed is, therefore, necessary to draw firm conclusions on any significant enrichment in specific gene contributions to the pathogenesis of this condition.

In the present study, among the 10 familial cases with mutations in *USH2A*, eight had an associated sensorineural hearing loss and were diagnosed as Usher syndrome type 2. This subgroup of patients with mutations in *USH2A* displayed a milder phenotype compared to a previously described cohort of syndromic and non-syndromic RP patients \[[@B26-ijms-21-00086]\]. In particular, BCVA was better than 20/40 in at least one eye in our pericentral RP patients with *USH2A* variants (average age: 50 years), whereas a large group of 105 patients with *USH2A* variants (mean age: 32 years; i.e., almost 20 years younger than our pericentral RP subgroup) showed a BCVA higher than 20/40 in 83% of subjects \[[@B26-ijms-21-00086]\]. Moreover, ERG response was more preserved, e.g., 30 Hz ERG in our *USH2A* pericentral RP patients (22 µV on average), while Sandberg et al. reported a mean amplitude of 6 µV in *USH2A* patients \[[@B26-ijms-21-00086]\].

Traditionally, RP has been studied through the main morphological and functional parameters such as visual acuity, GVF, and ERG. For this reason, we compared these measurements from our cohort of pericentral RP patients to those from patients with typical RP as well as from other cohorts of pericentral RP described in literature. Pericentral RP was found to be associated with a better visual acuity compared to typical RP. Indeed, almost all patients (85.2%) showed a preserved BCVA of 20/40 or better in at least one eye, in line with the previous studies on pericentral RP that reported a percentage of 71% and 94% \[[@B3-ijms-21-00086],[@B4-ijms-21-00086],[@B5-ijms-21-00086]\]. In particular, in a large US cohort of typical RP (about 900 cases), only 55% of subjects had a visual acuity of 20/40 or better \[[@B27-ijms-21-00086]\]. This percentage is even lower when considering older subgroups. For instance, Grover et al. \[[@B28-ijms-21-00086]\] reported that only 52% of typical RP patients aged ≥45 years had a visual acuity of 20/40 or better (84% in our cases with ≥45 years). Similarly, Berson et al. \[[@B29-ijms-21-00086]\] reported that 54% of RP patients aged ≥40 years had a visual acuity of 20/40 or better (85% in our cases aged ≥40 years). Furthermore, the GVF area estimated in pericentral RP was wider compared to typical RP, in agreement with the above-cited studies \[[@B3-ijms-21-00086],[@B4-ijms-21-00086],[@B5-ijms-21-00086]\]. In particular, the GVF area measured with V4e target appeared markedly more preserved in pericentral RP patients compared to a large cohort (*n* = 601) of typical RP patients recruited in a clinical trial investigating the effects of vitamin A treatment in RP \[[@B30-ijms-21-00086]\]. The baseline of this study reported an average area of about 2.000^°2^ \[[@B30-ijms-21-00086]\]. This difference is significant taking into consideration that subjects of an older age (\>50 years) and with more compromised visual function (i.e., VA \<20/200, GVF diameter \<8°, non-recordable ERG) were excluded from the latter study \[[@B30-ijms-21-00086]\]. Finally, 30 Hz ERG were more preserved in pericentral RP patients (average: 24 µV) compared to typical RP patients (average: 7 µV in subjects with mutations in *RHO* \[[@B24-ijms-21-00086]\]; 6 µV in subjects with mutations in *USH2A* \[[@B26-ijms-21-00086]\]; 2 µV in subjects with mutations in *RPGR* \[[@B31-ijms-21-00086]\]). Taken together, these features underline a better clinical course of pericentral RP compared to typical RP in agreement with the other studies on patients with pericentral RP \[[@B3-ijms-21-00086],[@B4-ijms-21-00086],[@B5-ijms-21-00086],[@B24-ijms-21-00086],[@B31-ijms-21-00086]\].

The OCT-based assessment of macular abnormalities revealed that the frequency of CME in pericentral RP patients (i.e., 16.0%) was comparable with that reported in our cohort of typical non-syndromic RP (22.9%) and Usher syndrome (15.7%). In contrast, the frequency of ERM (15%) was slightly lower in the pericentral RP cohort (typical non-syndromic RP: 19.8%; Usher syndrome: 19.0%). The other OCT findings (e.g., CRT and EZ width) were comparable with those in typical RP cohorts. FAF imaging revealed a pattern of hyper-autofluorescent ring in most subjects, similar to that observed in typical RP \[[@B32-ijms-21-00086],[@B33-ijms-21-00086]\].

Regarding intrafamilial variability, also Comander et al. \[[@B4-ijms-21-00086]\] described a case of two brothers harboring the same mutation in *PRPF31* but presenting different retinal phenotypes. One child showed a typical RP while the other displayed all the features of pericentral RP.

Mutations in the *CEP290* gene are reported as the most common (20%) cause of Leber congenital amaurosis (LCA) and they are more frequently associated with severe forms of retinopathies \[[@B34-ijms-21-00086],[@B35-ijms-21-00086]\]. In this study, we found two subjects (P10, P24) with mutations in *CEP290* among the cases with pericentral RP. P10 had a disease onset at the age of 5 years with reduction of visual field, preserved BCVA (20/20 in both eyes), constricted visual field with ring scotoma, subnormal dark-adapted 0.01 and light-adapted ERG responses ([Table 1](#ijms-21-00086-t001){ref-type="table"}, [Table S1](#app1-ijms-21-00086){ref-type="app"}). Patient P10 was found to be compound heterozygous for two pathogenic variants in *CEP290* (c.5709 + 2T \> G and c.384_385del) ([Table 2](#ijms-21-00086-t002){ref-type="table"}). P24 displayed an incidental diagnosis at the age of 12 years, preserved BCVA (20/20 in both eyes), peripheral visual field loss in the right eye and costricted visual field with ring scotoma in the left eye, subnormal dark-adapted 0.01 and light-adapted ERG responses ([Table 1](#ijms-21-00086-t001){ref-type="table"}, [Table S1](#app1-ijms-21-00086){ref-type="app"}). P24 was found to be compound heterozygous for two missense variants in *CEP290* (c.1664A \> T and c.1092T \> G) ([Table 2](#ijms-21-00086-t002){ref-type="table"}). To our knowledge, these are the first reported cases of *CEP290* defects associated with pericentral RP.

The current study has some limitations related to its retrospective and cross-sectional design. In particular, a single visit is available for most subjects in contrast to the study of Comander et al. \[[@B4-ijms-21-00086]\] in which 11 patients were evaluated on multiple visits. Moreover, some ophthalmological tests (i.e., OCT, FAF, MP) were not performed in all subjects. Nevertheless, our study, carried out for the first time on patients of European origin, adds important insights into the clinical presentation and genetic defects of pericentral RP. Interestingly, it expands the number of genes associated with the pericentral RP phenotype, including those involved in Usher and other syndromic conditions. In light of this finding, we suggest that whenever a pericentral RP is diagnosed, it is important to perform audio-vestibular examination, even in the absence of hearing symptoms, to unravel a potentially masked Usher syndrome. Moreover, the clinical characterization of our cohort confirms the mild phenotype of pericentral RP, particularly in terms of visual acuity, visual field and ERG responses. Finally, it highlights the high degree of intrafamilial phenotypic variability, even among siblings of a comparable age, suggesting that both genetic and environmental factors may act as disease modifiers.

4. Materials and Methods {#sec4-ijms-21-00086}
========================

4.1. Ethics Statement {#sec4dot1-ijms-21-00086}
---------------------

All procedures were approved by the Ethics Boards of the University of Campania 'Luigi Vanvitelli' (protocol n. 0008189/2015, 09.04.2015) and adhered to the tenets of the Declaration of Helsinki. Samples were collected upon written informed consent of the patient to sample collection and genetic analysis. For minors, informed consent was obtained by the parents or legal guardians.

4.2. Patients Inclusion Criteria {#sec4dot2-ijms-21-00086}
--------------------------------

The medical records of the patients were taken at the Referral Center for Inherited Retinopathies of the Eye Clinic of the University of Campania 'Luigi Vanvitelli' from November 2006 to June 2019. The patients were enrolled for the study on the basis of their retinal phenotype. The inclusion criteria were: bone-spicule pigmentation or atrophy in the near mid-periphery (5--30 degrees) within and beyond the vascular arcades, corresponding to an annular scotoma, normal appearance of optic disk macula and far retinal periphery ([Figure 1](#ijms-21-00086-f001){ref-type="fig"}); and subnormal, yet recordable, full-field ERG responses. Patients with a medical history of hydroxychloroquine use were excluded, since the toxicity induced by hydroxychloroquine (Plaquenil) has been reported as a non-genetic cause of the pericentral RP phenotype \[[@B36-ijms-21-00086]\].

To establish the onset of the disease, patients were questioned about the age at which they first noticed night vision problems and visual disturbances. The duration of the disease was calculated over time between the onset of symptoms and the date of the examination. Family history was also collected at the first visit. In case of incidental diagnosis, the age at diagnosis was considered as the disease onset.

Pedigree information was used to determine patterns of inheritance. RP was categorized as autosomal dominant (AD) (e.g., one affected parent and child, equal gender distribution), autosomal recessive (AR) (e.g., no affected parents, consanguinity) and sporadic (SP) cases (i.e., patients with no affected relatives).

4.3. Ophthalmological Examination {#sec4dot3-ijms-21-00086}
---------------------------------

All patients underwent a full ophthalmological examination which included: best-corrected visual acuities (BCVA) measured using the Snellen chart, slit lamp anterior segment examination, fundus examination, Goldmann visual field (GVF) examination, ERG, microperimetry (MP1), optical coherence tomography (OCT) and fundus autofluorescence (FAF) imaging.

GVF was measured in 49 patients by moving the III4e and V4e stimulus target on a calibrated standard Goldmann perimeter by the same experienced ophthalmic technician and was analyzed as previously published \[[@B37-ijms-21-00086]\].

Full-field ERG was recorded by corneal contact lens electrodes with a Ganzfeld stimulator (EREV 2000 Electrophysiology system; LACE Elettronica, Pisa, Italy) according to the recommendations of the International Society for Clinical Electrophysiology of Vision (ISCEV) \[[@B37-ijms-21-00086]\].

MP1 was performed in 19 patients by an automatic fundus-related perimeter (MP1 Microperimeter, Nidek Technologies, Padova, Italy). The following parameters were used: a fixation target of 2° in diameter consisting of a red ring; a white, monochromatic background with a luminance of 1.27 cd/m^2^; a Goldmann III-size stimulus with a projection time of 200 ms; and predefined automatic test pattern (Humphrey 10-2) covering 10° centred onto the gravitational centre of the fixation points with 68 stimuli.

OCT was performed in 50 patients with the spectral domain OCT (SD-OCT) (Cirrus HD-OCT, Carl Zeiss, Dublin, CA, USA) by an experienced operator. The acquisition protocol comprised both a five-line raster scan and a macular cube scan pattern (512 × 128 pixels) in which a 6 × 6 mm region of the retina was scanned within a scan time of 2.4 seconds.

FAF imaging was performed bilaterally in 24 patients according to the protocol reported by Aboshiha et al. \[[@B38-ijms-21-00086]\]. Briefly, fundus autofluorescence imaging of 30° field of view and 8 mm was acquired. Measurements of structures on FAF were performed using the Spectralis software with micrometer caliper. Temporal horizontal radius of the hyperautofluorescent ring (distance from fovea to inner and outer border) or patch was measured on the FAF image \[[@B39-ijms-21-00086]\]. FAF were classified following the patterns proposed by Fakin et al. \[[@B39-ijms-21-00086]\], i.e, hyperautofluorescent ring, hyperautofluorescent foveal patch and abnormal central hypoautofluorescence.

The patients referring extraocular abnormalities or bearing mutations in genes associated with syndromic conditions, whenever the clinical observation could not firmly exclude a syndromic form, underwent the appropriate specialist control (e.g., audiological visits for patients reporting hearing problems or harboring mutations in *USH2A*; dental and dermatological visits for patients harboring mutations in *PEX1*, etc.).

4.4. Next-Generation Sequencing {#sec4dot4-ijms-21-00086}
-------------------------------

Genomic DNA was extracted from peripheral blood using the DNeasy Blood and Tissue Kit (QIAGEN) according to the manufacturer's instructions. Samples were analyzed either by panel-based sequencing of known retinopathy-associated genes or by clinical exome sequencing using the ClearSeq Inherited Disease panel (Agilent). Libraries were sequenced on a NextSeq 500 sequencing platform (Illumina inc., San Diego, CA, USA) in collaboration with the NGS Core at the Telethon Institute of Genetics and Medicine (TIGEM).

4.5. Variant Analysis and Interpretation {#sec4dot5-ijms-21-00086}
----------------------------------------

Sequencing data were analyzed in collaboration with the Bioinformatics Core at TIGEM using a previously described in-house developed pipeline \[[@B40-ijms-21-00086]\]. The single nucleotide variants (SNVs) and indel variants were annotated as described \[[@B40-ijms-21-00086],[@B41-ijms-21-00086]\]. The alignments at candidate positions were visually inspected using the Integrative Genomics Viewer (IGV). To assess the possible deleterious effects of missense variants, in silico predictions of pathogenicity from the MutationTaster (<http://www.mutationtaster.org/>) \[[@B42-ijms-21-00086]\], Polymorphism Phenotyping v2 (Polyphen-2; <http://genetics.bwh.harvard.edu/pph2/>) \[[@B43-ijms-21-00086]\], Sorting Intolerant from Tolerant (SIFT; <http://sift.bii.a-star.edu.sg/>) \[[@B44-ijms-21-00086]\] and Combined Annotation-Dependent Depletion (CADD; <http://cadd.gs.washington.edu/>) \[[@B45-ijms-21-00086]\] tools were considered.

4.6. Variant Validation {#sec4dot6-ijms-21-00086}
-----------------------

The identified variants were validated by Sanger sequencing of the corresponding genomic fragments. For the amplification of the exon sequence, polymerase chain reaction (PCR) was performed on 20 ng of genomic DNA using Taq polymerase according to standard protocols. Amplicons were Sanger sequenced and mutation detection was performed using the CodonCode Aligner software. Segregation analysis was performed for the majority of patients (with only a few exceptions when parents' blood samples were not available).

We thank the participating patients and their families. The authors are grateful to the TIGEM Bioinformatics Core and the TIGEM NGS facility for support, and to the European Reference Network dedicated to Rare Eye Diseases (ERN-EYE) for useful discussions.

The following are available online at <https://www.mdpi.com/1422-0067/21/1/86/s1>, Table S1: Detailed clinical description of the pericentral RP cohort.
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Click here for additional data file.
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![Ophthalmic features of pericentral RP. (**a**) Goldmann visual field of a representative pericentral RP patient showing the typical pericentral scotomas and preserved peripheral field. (**b**) Composite fundus photograph showing the typical retinal phenotype with sparing of far periphery. (**c**) Fundus autofluorescence (FAF) image illustrating hypo-autofluorescence within and beyond the vascular arcades.](ijms-21-00086-g001){#ijms-21-00086-f001}

![Frequency of causative genes in the pericentral RP cohort. (**a**) Relative frequency of retinopathy genes mutated in the 23 familial cases with pericentral RP. (**b**,**c**) Prevalence for causative variants in genes associated also with syndromic retinopathies and in genes involved in ciliary function.](ijms-21-00086-g002){#ijms-21-00086-f002}

![Example of intrafamiliar phenotypic variability. (**a**) Pedigree of family n. 3. (**b**) Sanger sequencing traces of the two variants in exon 8 and exon 14 of the *PDE6B* gene in the two affected siblings (II:1, II:2) of family n. 3. (**c**) Composite fundus photograph of the proband (II:2, P4) and his 6 years older affected sister (II:1), revealing typical features of pericentral RP (left hand side) and sector RP (right hand side), respectively.](ijms-21-00086-g003){#ijms-21-00086-f003}

ijms-21-00086-t001_Table 1

###### 

Main clinical findings in the patients with pericentral retinitis pigmentosa (RP).

  Family   Gene Mutation   Patient   Age of Onset (yrs)   Age (yrs)   BCVA RE                               BCVA LE                               V4e Field Description RE              V4e Field Description LE
  -------- --------------- --------- -------------------- ----------- ------------------------------------- ------------------------------------- ------------------------------------- -------------------------------------
  F1       *PRPF31*        P1        8                    15          1                                     1                                     pericentral field loss                pericentral field loss
  P2       12              49        1                    1           constricted with peripheral scotoma   constricted with peripheral scotoma                                         
  F2                       P3        30                   55          0.8                                   1                                     constricted with ring scotoma         constricted with ring scotoma
  F3       *PDE6B*         P4        49                   52          0.9                                   0.9                                   constricted with ring scotoma         constricted with ring scotoma
  F4       *BBS2*          P5        15                   20          1                                     1                                     pericentral field loss                pericentral field loss
  F5                       P6        50                   84          0.2                                   0.4                                   n.a.                                  n.a.
  F6                       P7        31                   51          1                                     1                                     pericentral field loss                pericentral field loss
           P8              25        55                   0.7         0.9                                   constricted with ring scotoma         constricted with ring scotoma         
  F7       *RP1*           P9        47                   52          1                                     1                                     constricted with ring scotoma         constricted with ring scotoma
  F8       *USH2A*         P10       11                   47          1                                     1                                     constricted with ring scotoma         constricted with ring scotoma
  P11      38              58        0.7                  0.6         constricted with ring scotoma         constricted with ring scotoma                                               
  F9       *USH2A*         P12       14                   40          0.8                                   0.9                                   concentric constricted                concentric constricted
  F10      *CEP290*        P13       5                    34          1                                     1                                     constricted with ring scotoma         constricted with ring scotoma
  F11      *USH2A*         P14       20                   44          0.9                                   0.9                                   constricted with peripheral scotoma   constricted with peripheral scotoma
  F12      *PRPF31*        P15       4                    22          1                                     1                                     pericentral field loss                pericentral field loss
  P16      5               27        1                    1           constricted with peripheral scotoma   concentric constricted                                                      
  F13      *USH2A*         P17       11                   44          0.7                                   0.5                                   concentric constricted                concentric constricted
  F14      *PRPH2*         P18       27                   45          1                                     0.8                                   constricted with ring scotoma         constricted with ring scotoma
  F15                      P19       57                   76          0.0016                                0.0016                                n.a.                                  n.a.
  F16                      P20       47                   59          1                                     1                                     constricted with ring scotoma         constricted with ring scotoma
  F17                      P21       9                    27          0.1                                   0.1                                   pericentral field loss                pericentral field loss
  F18                      P22       36                   47          0.8                                   1                                     constricted with ring scotoma         constricted with ring scotoma
  F19                      P23       30                   53          1                                     0.9                                   constricted with peripheral scotoma   constricted with peripheral scotoma
  F20      *CEP290*        P24       12                   19          1                                     1                                     pericentral field loss                constricted with peripheral scotoma
  F21                      P25       41                   43          1                                     1                                     pericentral field loss                pericentral field loss
  F22      *RHO*           P26       9                    14          1                                     1                                     pericentral field loss                pericentral field loss
  F23      *PEX1*          P27       10                   11          0.3                                   0.3                                   pericentral field loss                pericentral field loss
  F24                      P28       34                   50          0.2                                   0.1                                   n.a.                                  n.a.
  F25      *USH2A*         P29       43                   49          0.1                                   0.7                                   n.a.                                  n.a.
  F26      *USH2A*         P30       15                   56          0.8                                   0.4                                   pericentral field loss                pericentral field loss
  F27                      P31       53                   59          0.6                                   1                                     constricted with ring scotoma         constricted with ring scotoma
  F28      *USH2A*         P32       42                   48          0.7                                   0.8                                   pericentral field loss                pericentral field loss
  F29                      P33       13                   20          0.9                                   0.6                                   pericentral field loss                pericentral field loss
  F30                      P34       5                    58          0.8                                   0.8                                   concentric constricted                concentric constricted
  F31      *PDE6B*         P35       19                   41          0.8                                   1                                     constricted with ring scotoma         constricted with ring scotoma
  P36      15              43        0.05                 0.05        constricted with ring scotoma         constricted with ring scotoma                                               
  F32      *NR2E3*         P37       0.67                 22          0.6                                   0.9                                   pericentral field loss                pericentral field loss
  P38      3               27        0.6                  0.6         pericentral field loss                pericentral field loss                                                      
  F33      *USH2A*         P39       40                   69          0.6                                   0.8                                   central scotoma                       central scotoma
  F34                      P40       49                   58          0.7                                   0.9                                   pericentral field loss                pericentral field loss
  F35                      P41       45                   64          0.6                                   0.5                                   concentric constricted                concentric constricted
  F36                      P42       5                    40          0.7                                   0.7                                   pericentral field loss                pericentral field loss
  F37                      P43       50                   78          0.1                                   0.05                                  concentric constricted                concentric constricted
  F38                      P44       55                   60          0.9                                   1                                     pericentral field loss                pericentral field loss
  F39                      P45       27                   71          1                                     0.4                                   n.a.                                  n.a.
  F40      *RP1*           P46       38                   42          0.9                                   0.6                                   pericentral field loss                pericentral field loss
  F41      *USH2A*         P47       24                   45          0.6                                   0.6                                   concentric constricted                concentric constricted
  F42                      P48       38                   44          1                                     0.9                                   constricted with ring scotoma         constricted with ring scotoma
  F43                      P49       14                   68          1                                     1                                     pericentral field loss                pericentral field loss
  F44                      P50       64                   80          0.8                                   0.8                                   concentric constricted                concentric constricted
  F45                      P51       6                    92          0.3                                   0.4                                   constricted with peripheral scotoma   constricted with ring scotoma
  F46                      P52       50                   77          0.6                                   0.5                                   pericentral field loss                pericentral field loss
  F47                      P53       18                   39          0.8                                   0.7                                   pericentral field loss                pericentral field loss
  F48                      P54       15                   33          0.9                                   0.9                                   pericentral field loss                pericentral field loss

Abbreviations: BCVA, Best-corrected visual acuity; LE, Left eye; n.a., not available; RE, Right eye.
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###### 

Genetic findings in the patients with pericentral RP.

  Patient   Family   Gene       RefSeq        Allele 1                                   Allele 2                                                                          
  --------- -------- ---------- ------------- ------------------ ----------------------- -------------------------- --- ---------------------- --------------------------- --------------------------
  *P1*      F1       *PRPF31*   NM_015629     c.3G \> A          p.(Met1Ile)             this study                     \-                     \-                          \-
  *P4*      F3       *PDE6B*    NM_000283     c.1107 + 3A \> G   p.(?)                   \[[@B6-ijms-21-00086]\]        c.1798G \> A           p.(Asp600Asn)               \[[@B7-ijms-21-00086]\]
  *P5*      F4       *BBS2*     NM_031885.3   c.401C \> G        p.(Pro134Arg)           \[[@B8-ijms-21-00086]\]        c.401C \> G            p.(Pro134Arg)               \[[@B8-ijms-21-00086]\]
  *P9*      F7       *RP1*      NM_006269     c.2219C \> G       p.(Ser740 \* )          this study                     \-                     \-                          \-
  *P46*     F40      *RP1*      NM_006269     c.2978delC         p.(Ser993Phefs \* 20)   this study                     \-                     \-                          \-
  *P10*     F8       *USH2A*    NM_206933     c.497A \> G        p.(Glu166Gly)           this study                     c.14977_14978del       p.(Phe4993Profs \* 7)       \[[@B9-ijms-21-00086]\]
  *P12*     F9       *USH2A*    NM_206933     c.9815C \> T       p.(Pro3272Leu)          \[[@B10-ijms-21-00086]\]       c.949C \> A            p.(Arg317Arg)               \[[@B11-ijms-21-00086]\]
  *P13*     F10      *CEP290*   NM_025114     c.5709 + 2T \> G   p.(?)                   this study                     c.384_385del           p.(Asp128Glufs \* 17)       \[[@B12-ijms-21-00086]\]
  *P14*     F11      *USH2A*    NM_206933     c.4732C \> T       p.(Arg1578Cys)          \[[@B9-ijms-21-00086]\]        c.14885dup             p.(Glu4963Glyfs \* 38)      \[[@B13-ijms-21-00086]\]
  *P15*     F12      *PRPF31*   NM_015629     c.690delG          p.(Ile231Serfs\*8)      this study                     \-                     \-                          \-
  *P17*     F13      *USH2A*    NM_206933     c.4717C \> T       p.(Gln1573\*)           \[[@B13-ijms-21-00086]\]       c.10712C \> T          p.(Thr3571Met)              \[[@B14-ijms-21-00086]\]
  *P18*     F14      *PRPH2*    NM_000322     c.458A \> G        p.(Lys153Arg)           LOVD ^‡^                       \-                     \-                          \-
  *P24*     F20      *CEP290*   NM_025114     c.1664A \> T       p.(Lys555Ile)           this study                     c.1092T \> G           p.(Ile364Met)               this study
  *P26*     F22      *RHO*      NM_000539     c.560G \> T        p.(Cys187Phe)           this study                     \-                     \-                          \-
  *P27*     F23      *PEX1*     NM_000466     c.274G \> C        p.(Val92Leu)            \[[@B15-ijms-21-00086]\]       c.2145_2146insTCTCAG   p.(Gln716delinsSerGlnGln)   this study
  *P29*     F25      *USH2A*    NM_206933     c.3045C \> G       p.(His1015Gln)          this study                     c.6992G \> A           p.(Gly2331Glu)              this study
  *P30*     F26      *USH2A*    NM_206933     c.2296T \> C       p.(Cys766Arg)           \[[@B16-ijms-21-00086]\]       c.2296T \> C           p.(Cys766Arg)               \[[@B16-ijms-21-00086]\]
  *P32*     F28      *USH2A*    NM_206933     c.11713C \> T      p.(Arg3905Cys)          \[[@B17-ijms-21-00086]\]       c.9959-1G \> C         p.(?)                       \[[@B18-ijms-21-00086]\]
  *P35*     F31      *PDE6B*    NM_000283     c.1798G \> A       p.(Asp600Asn)           \[[@B7-ijms-21-00086]\]        c.1798G \> A           p.(Asp600Asn)               \[[@B7-ijms-21-00086]\]
  *P37*     F32      *NR2E3*    NM_014249     c.119-2A \> C      p.(?)                   \[[@B19-ijms-21-00086]\]       c.119-2A \> C          p.(?)                       \[[@B19-ijms-21-00086]\]
  *P39*     F33      *USH2A*    NM_206933     c.2276G \> T       p.(Cys759Phe)           \[[@B20-ijms-21-00086]\]       c.3684T \> A           p.(Cys1228 \*)              \[[@B13-ijms-21-00086]\]
  *P47*     F41      *USH2A*    NM_206933     c.953A \> G        p.(Tyr318Cys)           LOVD ^‡^                       c.5776 + 1G \> C       p.(?)                       this study

^‡^ Leiden Open Variation Database.
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###### 

Pathogenicity predictions for the novel missense variants reported in this study.

  Gene       RefSeq      Nucleotide     Protein          In Silico Pathogenicity Analysis            
  ---------- ----------- -------------- ---------------- ---------------------------------- ---- --- ------
  *CEP290*   NM_025114   c.1664A \> T   p.(Lys555Ile)    LP                                 LP   P   27.8
  *CEP290*   NM_025114   c.1092T \> G   p.(Ile364Met)    LP                                 P    P   25.3
  *PRPF31*   NM_015629   c.3G \> A      p.(Met1Ile)      LP                                 B    P   23.8
  *RHO*      NM_000539   c.560G \> T    p.(Cys187Phe)    LP                                 P    P   24.8
  *USH2A*    NM_206933   c.497A \> G    p.(Glu166Gly)    LP                                 P    P   26.2
  *USH2A*    NM_206933   c.3045C \> G   p.(His1015Gln)   LP                                 LP   P   22.8
  *USH2A*    NM_206933   c.6992G \> A   p.(Gly2331Glu)   P                                  LP   P   28.9

^†^ <http://www.mutationtaster.org/>, ^‡^ Polymorphism Phenotyping v2; <http://genetics.bwh.harvard.edu/pph2/>, \* Sorting Intolerant from Tolerant; <http://sift.bii.a-star.edu.sg/>, ^\#^ Combined Annotation-Dependent Depletion; <http://cadd.gs.washington.edu/>, Abbreviations: B, benign; LP, likely pathogenic; P, pathogenic.

[^1]: These authors contributed equally to this work.

[^2]: Co-senior authors.
